Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS


Creative Commons License

YÖYEN ERMİŞ D., Tunali G., Tavukcuoglu E., Horzum U., Ozkazanc D., SÜTLÜ T., ...More

SCIENTIFIC REPORTS, vol.9, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9
  • Publication Date: 2019
  • Doi Number: 10.1038/s41598-019-48256-4
  • Title of Journal : SCIENTIFIC REPORTS

Abstract

Interferon (IFN)-gamma is the major mediator of anti-tumor immune responses; nevertheless, cancer cells use intrigue strategies to alter IFN-gamma signaling and avoid elimination. Understanding the immune regulatory mechanisms employed by acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cells upon exposure to IFN-gamma is critical for development of immunotherapy and checkpoint blockade therapy approaches. This study aims to explore the influence of myeloid maturation on IFN-gamma-induced PD-L1 and PD-L2 expression and on pro-leukemogenic transcription factor STAT3 signaling in AML and MDS. Stimulation of myeloid blasts' maturation by all-trans retinoic acid (ATRA) or 1 alpha,25-dihydroxyvitamin D3 (vitamin D) increased the CD11b(+) fraction that expressed PD-1 ligands in response to IFN-gamma. Intriguingly, STAT3 pathway was potently induced by IFN-gamma and strengthened upon prolonged exposure. Nonetheless, STAT3-mediated atypical IFN-gamma signaling appeared as a negligible factor for PD-L1 and PD-L2 expression. These negative influences of IFN-gamma could be alleviated by a small-molecule inhibitor of STAT3, stattic, which also inhibited the upregulation of PD-L1. In conclusion, induction of myeloid maturation enhances the responsiveness of AML and MDS cells to IFN-gamma. However, these malignant myeloid cells can exploit both STAT3 pathway and PD-1 ligands to survive IFN-gamma-mediated immunity and maintain secondary immune resistance.